Femprox is more for FSAD, women who have desire but have difficulty with lubrication, orgasm, sensitivity, local arousal, etc..
BMT is more for women with psychological issues of no interest, no sexual thoughts. So there are 2 categories. So yes, BMT could be preferred in that category of no interest but it will not capture the whole FSD market, imo. It's still a sizable market for BMT if they can get results far enough above placebo, which is the Flibaserin problem.
How much more safe or efficacious is BMT compared to Flibaserin, Flibaserin is now limiting their approach to pre-menopausal women , where they had better results in their most recent studies, same with Femprox, femprox is going pre-menopausal in the EU first, since the FDA is so hard to crack.
Recent PTN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 02:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 02:00:32 PM
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results • PR Newswire (US) • 11/14/2024 12:30:00 PM
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 • PR Newswire (US) • 11/08/2024 02:57:00 PM
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 • PR Newswire (US) • 11/04/2024 12:30:00 PM
- Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity • PR Newswire (US) • 10/31/2024 11:30:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/30/2024 01:07:01 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/30/2024 04:15:05 AM
- Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium • PR Newswire (US) • 10/24/2024 11:30:00 AM
- Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium • PR Newswire (US) • 10/23/2024 11:30:00 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/22/2024 08:31:17 PM
- Palatin Receives Notice of Non-Compliance from NYSE American • PR Newswire (US) • 10/07/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:15:23 PM
- Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 10/01/2024 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/30/2024 08:31:04 PM
- Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results • PR Newswire (US) • 09/26/2024 11:30:00 AM
- Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 09/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:35:29 PM
- FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) • PR Newswire (US) • 08/28/2024 11:30:00 AM
- First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 08/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/25/2024 08:46:11 PM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM